Germany’s cannabis industry is making history. What seemed like a regulatory experiment just a few years ago has evolved into a highly professional economic sector. The latest data from the Federal Institute for Drugs and Medical Devices (BfArM) confirms what market observers have suspected for months: Germany’s appetite for medical cannabis is greater than ever before.
📑 Inhaltsverzeichnis
A Historic Import High
In calendar year 2025, the industry reached a decisive milestone: for the first time, over 200 tons of medical cannabis were imported into Germany. For comparison, just five years ago, import volumes were in the low double digits.
This massive increase is no accident, but the result of growing acceptance within the medical profession and an optimized logistics chain. The country has established itself as the undisputed anchor point of the European market. While other EU nations are still wrestling with pilot projects, Germany is providing the infrastructure for comprehensive patient care.
International Players in the Gold Rush
The economic implications are already evident. In particular, international corporations are benefiting from Germany’s dynamic growth. On March 17, 2026, industry giant High Tide released its latest quarterly report, making waves in the markets.
The company reported record revenues in its Germany segment, underscoring the strategic importance of the domestic market. For global players from Canada, Israel, and Australia, Germany is no longer just an interesting export destination—it has become the decisive revenue driver in their balance sheets. The message is clear: anyone wanting to play a role in the global cannabis business must succeed in Germany.
Market Development: Annual Cannabis Import Volumes to Germany
| Year | Import Volume (in tons) | Growth vs. Previous Year |
|---|---|---|
| 2021 | ~21 t | — |
| 2022 | ~35 t | + 67 % |
| 2023 | ~78 t | + 122 % |
| 2024 | ~145 t | + 86 % |
| 2025 | > 200 t | + 38 % |
Supply Chain Professionalization
Behind these raw numbers lies a profound professionalization. Importing over 200 tons requires:
- Enhanced Quality Standards: Only GMP-certified (Good Manufacturing Practice) products make their way into German pharmacies.
- Efficient Bureaucracy: The approval processes at the BfArM have been significantly digitized and accelerated over the past 24 months.
- Diversified Sources: While early imports came almost exclusively from Canada, producers from other European countries (such as Portugal and Denmark) now supply Germany directly.
Where Is the Limit?
Industry experts believe the 200-ton milestone represents just one milestone along the way. With increasing digitalization of prescription pathways through telemedicine and an aging population turning to cannabis-based pain therapies, demand could target the 300-ton threshold by 2028.
Germany has proven it can manage a highly complex, controlled distribution system for controlled substances on an industrial scale. One thing is certain: the green wave has firmly arrived in the mainstream of Germany’s economy.
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
